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“You can't quit now. What if the Great Valley's just over the top of these rocks?” 
(in The Land Before Time, 1988) 
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RESUMO 
 
O manganês (Mn) é um metal essencial, necessário para o normal desenvolvimento dos 
organismos vivos. Tem um papel importante no crescimento ósseo, no metabolismo das 
proteínas, lípidos e hidratos de carbono e como co-factor de diversas enzimas como por 
exemplo a superóxido dismutase (SOD), importante na defesa contra os radicais oxidantes.  
O Mn é ubíquo e ocorre naturalmente no ambiente como constituinte de uma grande 
variedade de minerais (óxidos, fosfatos, carbonatos, etc.), na água e nos alimentos. O Mn é 
muito usado na indústria, no fabrico de ligas metálicas (nomeadamente do aço), na síntese 
de fertilizantes e fungicidas e como aditivo em combustíveis fósseis. Os alimentos são 
normalmente a fonte de exposição mais relevante para a população. Em condições normais 
as concentrações de Mn no organismo são mantidas constantes por mecanismos 
homeostáticos e o excesso é eliminado do organismo. No entanto, podem ocorrer casos de 
sobreexposição, normalmente associada à exposição ocupacional. Uma exposição crónica 
a elevadas concentrações de Mn pode originar diversos efeitos tóxicos principalmente a 
nível neurológico.  
O cérebro é o órgão-alvo na intoxicação pelo Mn. O manganismo é uma doença crónica 
neurodegenerativa que resulta de uma intoxicação crónica pelo Mn. Os casos detectados e 
descritos de manganismo caracterizam-se por elevadas concentrações de Mn nos gânglios 
basais e uma perda progressiva e irreversível de neurónios dopaminérgicos no globus 
pallidus e zonas adjacentes. E embora se reconheça a citotoxicidade do Mn, o mecanismo 
pelo qual ela ocorre ainda não está completamente esclarecido. Vários estudos apontam o 
stress oxidativo como responsável pelos efeitos provocados pelo Mn. O stress oxidativo é 
um processo que resulta de um desequilíbrio entre espécies pró-oxidantes e antioxidantes 
que conduz a um aumento intracelular de espécies oxidantes.  
Um dos mecanismos que podem explicar a toxicidade do Mn é via oxidação da dopamina e 
outras catecolaminas. Pensa-se que elevadas concentrações de Mn possam acelerar a 
oxidação da dopamina e consequentemente acelerar o processo de formação das espécies 
reactivas de oxigénio (ROS). Outra possibilidade, será a de que a acumulação de Mn nas 
mitocôndrias interfira com a respiração mitocondrial, levando também a uma excessiva 
produção de ROS. 
Ao nível celular, tem sido demonstrado que o Mn diminui a quantidade de glutationa (GSH) 
e outros tióis e de catalase. O aumento da formação de ROS por acção do Mn e a 
diminuição dos níveis de antioxidantes pode desequilibrar a estabilidade celular.  
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Antioxidantes tais como a GSH, o ácido ascórbico e a N-acetil-cisteína, podem promover 
uma diminuição das ROS, protegendo as células de danos e/ou da morte celular. 
Um dos grandes desafios ligados ao estudo da neurotoxicidade do Mn é a descoberta e 
validação de indicadores biológicos que permitam prevenir e identificar a ocorrência de 
neurotoxicidade originada pela exposição ao Mn. Habitualmente, para avaliação da 
exposição de populações ao Mn, recorre-se à determinação das concentrações de Mn no 
sangue e/ou urina. Mas devido à toxicocinética do Mn, estes indicadores só informam 
acerca de uma exposição recente ao Mn, não fornecendo informação acerca exposições 
anteriores. Assim, embora permitam distinguir entre grupos expostos e não-expostos, não 
informam acerca de possíveis efeitos nefastos que podem estar em desenvolvimento como 
consequência de exposições anteriores ao Mn. é assim essencial o desenvolvimento de 
novos biomarcadores no sentido de prevenir efeitos neurotóxicos originados pela exposição 
ao Mn. 
Para além destes biomarcadores de exposição, existem outros, os de efeito, que podem 
revelar algumas alterações biológicas provocadas pelo efeito tóxico do Mn. Os níveis de 
GSH, um dos principais antioxidantes celulares são um exemplo. A intoxicação pelo Mn tem 
sido associada a um decréscimo dos níveis de GSH celulares, como consequência directa 
da acção das ROS.  
Mas existem outros marcadores já testados, mas controversos e não validados, como a 
prolactina. A prolactina é apontada como um indicador da função dopaminérgica. Na 
hipófise, a dopamina suprime a actividade secretora dos lactoforos, que produzem a 
prolactina. O motivo da inclusão da prolactina baseou-se no facto da exposição ao Mn 
causar distúrbios no cérebro ao nível da dopamina e desta servir como inibidor da libertação 
de prolactina na parte endócrina da hipófise, como já foi referido.  
Numa perspectiva de protecção da saúde humana propusemo-nos assim estudar 
biomarcadores de exposição e efeito que ajudem a prevenir e identificar a ocorrência de 
neurotoxicidade originada pela exposição ao Mn e tentar perceber a relação exposição-
efeito. Propusemo-nos ainda estudar a acção do antioxidante ebselen na toxicidade do Mn.  
Assim, foi realizado um ensaio in vivo com ratos Wistar repetidamente expostos a MnCl2, 
via intraperitoneal (4 e 8 doses consecutivas). A exposição ao Mn foi avaliada recorrendo à 
determinação dos níveis de Mn no sangue e no cérebro. Após a exposição ao Mn (4 e 8 
doses) verificaram-se níveis significativamente elevados de Mn no cérebro, quando 
comparados com o controlo (p>0.0001). Por outro lado, os níveis de Mn no sangue, não 
reflectiram a acumulação no cérebro, uma vez que só relativamente à dose mais alta (8 
doses) é que se obtiveram valores elevados e significativos. Para além da monitorização da 
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exposição, foram também estudados biomarcadores de efeito, na tentativa de correlacionar 
estes últimos com os de exposição. Para tal, os níveis de GSH no cérebro foram 
determinados e foi observada uma diminuição dos seus níveis, nos animais expostos ao 
Mn. Essa diminuição só foi significativa para a exposição mais elevada (8 doses; p>0.0001). 
Foram ainda determinadas as concentrações da hormona prolactina, no soro. Estudos 
anteriores já haviam incluído esta determinação para tentar avaliar o seu potencial como 
bioindicador de neurotoxicidade, mas com resultados contraditórios e inconclusivos. Neste 
estudo, a prolactina revelou-se um indicador sensível e expressivo, com aumentos da 
concentração proporcionais às doses administradas.  
Relativamente aos efeitos do ebselen, verificaram-se diferenças na acumulação do Mn no 
cérebro, quando o ebselen está presente. Ratos tratados com Mn e ebselen 
simultaneamente (8 doses) acumularam significativamente menos Mn no cérebro que os 
controlo (p>0.0001). No que diz respeito ao efeito antioxidante, o ebselen não parece 
proteger contra o stress oxidativo, nas concentrações administradas, uma vez que o 
composto não ofereceu protecção contra o decréscimo dos níveis de GSH.  
Finalmente no que diz respeito ao estudo das possíveis interferências do Fe na acumulação 
do Mn no cérebro, estudada através da medição dos níveis de Fe no cérebro, não se 
obtiveram diferenças significativas, o que não permite que se tirem conclusões acerca do 
papel deste metal na toxicocinética do Mn. 
 
PALAVRAS-CHAVE: manganês; ensaios in vivo; biomarcadores; prolactina; antioxidantes; 
ebselen 
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ABSTRACT 
 
Manganese (Mn) an essential nutrient for several animal species is required for normal 
aminoacid, lipid, protein and carbohydrate metabolism. However, chronic exposure to this 
metal can originate accumulation in the brain, leading to adverse health effects, particularly 
in the central nervous system. Although the exact mechanism of Mn toxicity is not 
completely established, several studies indicate that oxidative stress plays a major role in 
the Mn-induced toxicity process. To avoid overexposure and the consequent neurotoxic 
effects, people chronically exposed must be monitorized recorring to adequate biomarkers.  
The aim of this study was to examine the correlation between exposure and effect 
biomarkers and the possible protective effect of ebselen, a compound with antioxidant 
properties, against Mn toxicity. In an in vivo assay rats were exposed to several doses of Mn 
(4 and 8 doses) by intraperitoneal injection of manganese chloride (10.0 mg/kg). 
The exposure to Mn was evaluated by measuring Mn levels in the brain and blood. Mn levels 
in brain were increased and significantly different from control (p<0.0001, for both doses). 
On the other hand, blood levels failed to evidence the accumulation of Mn in the brain in a 
dose-dependent manner, with only 8 doses group showing significant differences 
(p<0.0001). The levels of reduced glutathione (GSH) in the brain were assessed as an 
indirect indicator of oxidative stress and prolactin levels in serum were analyzed. GSH levels 
were significantly decreased in 8 doses treated animals (p<0.0001). Prolactin was shown to 
be a valuable indicator of the neurotoxic effects of Mn, since significant and dose-dependent 
increase was found for both treated groups (p<0.0001). In addition a decrease in motor 
activity was observed in the 8 doses group. 
Finally, ebselen evidenced a protective effect against Mn accumulation in the brain, for the 8 
doses group (p<0.0001). Yet, it doesn’t seem to protect against oxidative stress since 
decreased values of GSH were observed. 
 
KEYWORDS: manganese; in vivo assays; biomarkers; prolactin; antioxidants; ebselen 
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INTRODUCTION  
 
 
Never take the antidote before the poison (Latin proverb) 
 
 
MANGANESE – HISTORY AND MAIN USES 
 
Manganese (Mn) is an abundant and nutritionally essential trace metal that has been used 
by men since the Stone Age. Back there, 17000 years ago, Mn dioxide (MnO2) was used 
as a pigment for cave paintings. The Spartans in Ancient Greece had weapons made of 
iron and Mn ores and the Egyptians and the Romans used Mn to decolorize glass or 
change its color.  
Nowadays Mn is mainly used in metallurgical processes to improve the properties of alloys 
such as steel; it is also used in non-metallurgical processes like dry-cell batteries 
production, in several chemical processes and in the pharmaceutical industry [1]. Mn has 
been used in the form of MMT (C9H7MnO3 methylcyclopentadienyl Mn tricarbonyl) to 
substitute lead organic compounds in gasoline, raising concern for the health of urban 
populations exposed to automobile fumes [2], [3].  
 
 
PHYSICAL AND CHEMICAL PROPERTIES AND BIOLOGICAL ROLE 
 
Mn is a grey-white transition metal. It has an atomic number of 25 and belongs to Group 
VII of the Periodic Table [4]. The name Mn derives from the Latin magnes meaning 
"magnet" since the most common Mn mineral pyrolusite, has magnetic properties. Mn was 
discovered in 1774 by the Swedish chemist Carl-Wilhelm Scheele and it was first isolated 
in the same year by Scheele’s assistant Johan Gottlieb Gahn.  
Mn shares numerous physical and chemical properties with iron (Fe), another transition 
metal. They are both adjacent to each other in the periodic table, both can have valence 
states +2 and +3 in physiological conditions, they show similar ionic radius, strongly bind 
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transferring, and both accumulate in the mitochondria [5-7]. Mn oxidation states range 
from -3 to +7, but the most commons are +2, +3, +4, +6 and +7. 
 
Mn is crucial for many metabolic and cellular functions [7]. It is needed for normal immune 
function, regulation of blood sugar and cellular energy, reproduction, digestion, bone 
growth, and aids in defense mechanisms against free radicals [8, 9]. It is required for 
normal amino acid, lipid, protein and carbohydrate metabolism [9], and is a co-factor for 
Mn superoxide dismutase (Mn-SOD) an enzyme critical in preventing cellular oxidative 
stress, for arginase which is responsible for the production of urea in the liver, for 
glutamine synthetase, the enzyme responsible for the generation of the neurotransmitter 
glutamate, and phosphoenolpyruvate decarboxylase [7], [10, 11].  
 
Inadequate dietary intake and Mn deficiency, although not frequently encountered, leads 
to alterations in levels of cholesterol, calcium, phosphorus and alkaline phosphatase in 
blood, and also skin disturbances [12]. 
 
 
Mn IN THE ENVIRONMENT  
 
Mn has a ubiquitous distribution in the environment, representing 0.1% of the Earth crust. 
It is the 12th most abundant element in the crust and the fifth most abundant metal [13], 
[14]. Its abundance is estimated to be from 0.085 to 0.10 percent which makes it about as 
abundant as fluorine or phosphorus.  
Crustal rock is the major source of the Mn found in the atmosphere [13]. Crustal Mn can 
enter the atmosphere by both natural events and/or anthropogenic processes.  
 
 
NATURAL SOURCES 
 
Mn does not occur naturally as a pure metal (elemental form), but as a constituent of more 
than 100 minerals, including many sulfides, oxides, carbonates, silicates, phosphates, and 
borates [13]. 
Study of biomarkers to evaluate the protective effects of antioxidants against manganese neurotoxicity 
CHAPTER I - INTRODUCTION 
3 
 
South Africa and the former Soviet Union have more than 80% of the world’s land-based 
Mn resources. Substantial Mn reserves also exist on the deep ocean floor but these are 
currently unavailable for commercial exploitation [1]. Natural sources include ocean spray, 
forest fires, vegetation, and volcanic activity. Stokes et al. estimated that two-thirds of Mn 
air emissions were from natural sources [15]. Air erosion of soils is also an important 
atmospheric source, but it wasn’t identified any quantitative estimates of Mn release to air 
from this source were identified [13]. The suspension of soil particles occurs specially 
during agricultural, construction and quarrying activities [14].  
 
 
ANTHROPOGENIC SOURCES 
 
The major anthropogenic sources of environmental Mn include municipal wastewater 
discharges, sewage sludge, mining and mineral processing (particularly nickel), emissions 
from alloy, steel, and iron production, combustion of fossil fuels, and, to a much less 
extent, emissions from the combustion of fuel additives.  
Problems with air pollution due to Mn — especially dust and smoke containing Mn dioxide 
and Mn tetroxide — arise during the mining, crushing, and smelting of ores as well as 
during steel production [13]. Coarse particles of Mn tend to settle out near sources of 
pollution, but fine particulate Mn can be distributed very widely [14]. In 1996, there were 
4000 tonnes of estimated releases of Mn into air in the United States of America (USA), 
representing 15% of total environmental releases [16]. Mn release to air occurs as a 
consequence of the manufacture of ferroalloys and other industrial processes but also as a 
result of the combustion of fossil fuels, namely those containing MMT. MMT was first used 
as an additive of gasoline to increase the octane rating and later to substitute lead organic 
compounds. It was banned from the United States of America in the 70’s and re-
introduced in the 90’s. Ethyl Corp. (a major producer of MMT) confirmed that MMT is now 
sold in 25 countries.  
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SOURCES OF EXPOSURE TO Mn 
 
 
FOOD 
 
Once Mn is a natural component of the environment, populations are always exposed to 
low levels in water, air, and food. 
The most significant source of Mn exposure for the general population is food [13, 17]. The 
United States National Research Council (NRC) has established an estimated safe and 
adequate dietary intake (ESADDI) of 2–5 mg of Mn/day for adults [17] and the Scientific 
Committee for Food of the European Union estimated 1-10 mg/day as an acceptable 
range of intake [18]. The adequate intake is 2.3 and 1.8 mg/day for adult men and women, 
respectively [19]. 
Mn intake among individuals varies greatly, depending on dietary habits [20]. Intake can 
be higher for vegetarians because higher levels of Mn occur in plants. Tea and leafy green 
vegetables were found to be important dietary sources of Mn (a cup of tea can have 
between 0.4−1.3 mg/cup) [21]. Important sources of dietary Mn also include grain, rice, 
and nuts (≈30 mg Mn/kg). 
 
 
WATER 
 
Mn intake from drinking water is normally substantially lower than the intake from food. For 
an adult, the intake of Mn from drinking water should be 20 µg/day, assuming a daily water 
intake of 2 L [20]. Mn concentrations in drinking water range from 1-100 µg/l, with most 
sources containing less than 10 µg/l [8]. The USA Environment Protection Agency (EPA) 
limit for Mn in drinking water is 50 µg Mn/L in order to prevent visual discoloration and 
undesirable taste [22]. 
Mn also occurs naturally in surface and groundwater. Natural concentrations of Mn in 
seawater reportedly range from 0.4-10 µg/L [20]. Higher levels (1–200 µg Mn/L) typically 
occur in freshwater [22]. Human activities can be responsible for Mn contamination of 
water in some areas. 
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AIR 
 
EPA established an inhalation reference concentration (RfC) for respirable Mn of 0.05 
µg/m3. [23]. Several studies revealed that air concentrations are in general below this 
value [20]. 
Natural background levels of Mn in air are low, ranging from 0.006 to 0.027 µg/m3. In rural 
areas, Mn concentrations may range from 0.01 to 0.03 µg/m3. In urban areas without 
important industrial sources of Mn, its levels may range from 0.01 to 0.07 µg/m3 while near 
industrial sources, levels can range from 0.2 to as high as 0.5 µg/m3 [24]. The intake of Mn 
through inhalation of environment air was estimated by the World Health Organization 
(WHO) to be about 2 µg/day [1]. In areas with major foundry facilities, exposure may rise 
to 4-6 µg/day and in areas associated with ferro- or silico Mn industries it may be as high 
as 10 µg/day with some values exceeding 200 µg/day [20]. 
 
 
OCCUPATIONAL EXPOSURE 
 
Occupational exposure is associated with working environments from several industries 
including: mining, production of Mn metal and metal alloys, chemical production of Mn-
based chemicals, steel production (and other metal smelting processes), welding, battery 
manufacture, agricultural products (production and use), pigments, paints and glass 
industry production [1]. In workplaces, exposure to Mn occurs mainly by inhalation of Mn 
fumes or Mn-containing dusts [20]. 
These occupational environments tend to have higher Mn levels [20]. Concentrations of 
1.5–450 mg Mn/m3 have been reported in USA Mn mines, 0.30–20 mg Mn /m3 in ferroalloy 
production facilities, and 3–18 mg Mn /m3 in a dry-cell battery facility. These values are 
sometimes more than 100 times the values estimated for environment air exposure.  
As a result, inhalation exposure to Mn can vary from quite low (environmental) to high 
levels (occupational) and the impact of these exposures will likewise range from negligible 
to toxicologically significant levels [23]. The WHO recommended an OEL (occupational 
exposure limit) of 0.3 mg/m3 for respirable Mn particles [1].  
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MANGANISM 
 
Many cases of Mn neurotoxicity (manganism) have been reported particularly in miners, 
smelters, and workers involved in the alloy industry. Manganism is a neurological disease 
similar to Parkinson’s disease (PD) and was first described in the 19th Century by Couper 
(1897), as an extrapyramidal dysfunction with neuropsiquiatric symptoms. Manganism is 
also known as Welding-related Parkinsonism or Mn-induced Parkinsonism. 
The disease is initially characterized by non-specific signs and symptoms such as 
headache, muscles cramps, fatigue, sleep disturbances, and irritability [24, 25]. In a later 
stage, people may experience various psychiatric symptoms like hallucinations, emotional 
lability, psychosis and some movement disorders such as muscular weakness, tremor, 
bradykinesia, dystonia [26], [25]. Some of these symptoms are common to different forms 
of Parkinsonism and the diagnosis may be difficult. Nevertheless, clinical data, response to 
levodopa and neuroimaging studies can differentiate PD from Mn-induced Parkinsonism 
[26], [27]. 
Several studies indicate that the neuropathological basis of this condition is associated 
with damage to basal ganglia structures. The nuclei comprising these structures are 
responsible for integrating and coordinating information from various brain regions 
associated with motor movement, which can explain the movement disorders observed in 
the patients. T1-weighted magnetic resonance imaging (MRI) can detect Mn in the basal 
ganglia with elevated Mn levels in the globus pallidus, striatum and substantia nigra pars 
reticulata [24], [26], [28], [29]. PD affects mainly the substantia nigra pars compacta and 
may have a normal MRI [5], [30]. Cumulative exposure may be an important aspect of the 
development of the disease [26].  
Lack of effective treatment for chronic manganism has been a major obstacle in clinical 
management of occupational Mn intoxication [31]. In some cases there was a slow 
recovery after exposure cessation but in most cases, chronic exposures have resulted in 
permanent neurological damage [24]. Calcium disodium ethylenediamine tetraacetic acid 
(EDTA) administration was shown to increase the excretion of Mn in urine [32] but it has 
low ability to repair the damaged neurons and it shows little practical benefit for severe Mn 
poisoning treatment. A 2006 study suggested antibacterial drug sodium para-
aminosalicylic acid (PAS) as a possible effective treatment for severe chronic Mn 
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intoxication with a promising long-term prognosis. However, some important questions 
remain unanswered, for instance the brain barrier permeability to PAS [31].
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STATE OF THE ART 
 
 
MN TOXICOKINETICS: OVERVIEW 
 
ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION 
 
In general, Mn levels in organs are kept low and constant due to homeostatic 
mechanisms. Since Mn is an essential metal that can be toxic in several circumstances, its 
homeostasis is vital for the optimal functioning of organisms [5], [33]. In 1954, Cotzias and 
Maynard injected radioactive Mn (Mn56) in rats and observed that Mn clearance from the 
blood was both rapid and extensive [34]. Mn has a relatively short blood half life (t1/2 < 2 h) 
and large volume of distribution, disappearing rapidly from the blood compartment [35]. 
Under normal conditions blood Mn levels are maintained by both gastrointestinal (GI) 
absorption and by efficient removal from the liver. Only a small fraction (1–5%) of the 
ingested Mn is absorbed [23]. According with Garcia-Aranda and collaborators (1983) Mn 
absorption is a rapid saturable process [36]. The mechanism(s) by which Mn is absorbed 
from the GI tract is incompletely understood but it is likely to include passive diffusion and 
active transport. Mn absorption from the GI tract is extremely complex and is influenced 
not only by the amount of Mn in the diet (when high, GI absorption of Mn is greatly 
reduced) but also by Fe and certain other nutrients. In particular, Fe deficiency is a 
frequent risk factor that can result in increased Mn absorption from the GI tract and 
enhanced brain delivery of Mn [23]. Furthermore, ingestion of high Fe vs. marginal levels 
of Fe increased Mn true absorption and inhibited 54Mn retention in whole animals and 
tissues [37].  
The liver is the major route for Mn elimination playing a vital role in regulating Mn levels in 
vivo. Dietary Mn is transported to the liver after absorption by the GI tract [38] where it 
forms complexes with bile components [5]. Biliary excretion is the main mechanism by 
which Mn is excreted in the feces and removed from the body [23], [39]. 
 
Mn distribution in tissues is not homogeneous. After an intraperitoneal injection (i.p), Mn is 
rapidly distributed, concentrating primarily in organs rich in mitochondria [40]. The highest 
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concentrations of Mn appear in the bones and in active metabolic organs: liver, pancreas, 
pituitary gland, adrenal glands, and kidneys [41].  
The brain is the major target organ for Mn toxicity. It retains Mn much longer than other 
tissues (half-life of 34 days in rats) [10], [41].  
 
 
MN TRANSPORT INTO THE BRAIN 
 
 
BLOOD – BRAIN BARRIER  
 
The Nervous System (NS) is protected from the adverse effects of potential toxicants by 
an anatomic barrier, an interface between the blood and the brain, the blood–brain barrier 
(BBB) [19, 42]. Most of the brain, spinal cord, retina, and peripheral NS (PNS) maintain 
this barrier with the blood, with a selectivity similar to the interface between cells and the 
extracellular space [19]. The barrier that separates the systemic circulation from the 
cerebrospinal fuid (CSF) compartment is known as the blood–CSF barrier (BCB) [43].  
The BBB is formed primarily by the endothelial cells of blood capillaries in the brain. 
Among the unique properties of endothelial cells in the NS is the presence of tight 
junctions between cells [19]. The endothelial cells are surrounded by a basement 
membrane consisting of collagen and other lipophilic matrix proteins, which together slow 
the diffusion of water-soluble compounds. Endothelia cells and glial cells connect with the 
basement membrane composing the physical BBB, which inhibits absorption transport 
between the blood and brain [10]. 
For most solutes and macromolecules, permeability across the BBB is dependent upon 
their lipophilicity and size. Small water-soluble nutrients and macromolecules needed for 
proper brain functioning can cross the barrier through specific carrier mechanisms or 
facilitated diffusion.  
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TRANSPORT AND ACCUMULATION 
 
Mn can enter the brain through the capillary endothelial cells of the BBB, by the choroid 
plexus of the blood–CSF barrier, or via the olfactory nerve from the nasal cavity directly to 
the brain [10], [29].  
Crossgrove and Zheng notice a readily transport of Mn through the blood–brain barrier and 
accumulation in specific brain regions namely the choroid plexus [10]. The influx to the 
choroid plexus is about 150 and 1000 times greater than that of cerebral cortex and CSF, 
when the plasma concentration of Mn is maintained constant [43]. This particularity can be 
explained since the capillary endothelial cells within the choroid plexus tissue lack tight 
junctions [10]. 
Several investigators have shown that Mn bioavailability, transport and retention in the 
brain also depend on the oxidation state of Mn [34], [43], [44]. Yet, how Mn is transported 
into the brain is still controversial. Various mechanisms have been identified, including 
active transport and facilitated diffusion. More recently, it has been established that Mn 
can also be transported via high affinity metal transporters such as calcium (Ca2+) and Fe 
transporters. Some of these transporters include the divalent metal transporter (DMT1), 
ZIP-8, a member of the solute carrier-39, Tf receptor (TfR), which is known to be 
responsible for Fe3+ uptake, voltage regulated and store-operated Ca2+ channels, and the 
ionotropic glutatmate receptor Ca2+ channels [33]. Several studies have reported that Mn 
accumulation in the central nervous system (CNS) is elevated during iron deficiency, 
supporting the hypothesis that DMT1 is involved in this uptake process [29].  
Considering that both Fe and Mn are required for normal CNS function and that Mn is 
neurotoxic in elevated concentrations, it is important to understand the mechanisms 
underlying the transport processes to the brain and the stringent regulation of the 
concentration of these metals within the brain [45]. 
Divalent Mn generally bounds to β-globulin and albumin, while trivalent Mn (Mn3+) bounds 
to transferrin (Tf) [23]. The Tf dependent pathway proposes that the transferrin-Mn3+ 
complex initially binds to the TfR on the cell surface similar with iron transport. Since Mn2+ 
(divalent Mn) forms a relatively weak complex with either α-2-macroglobulin or serum 
albumin, there is also the possibility that Mn2+ transport released from this complex can be 
taken up directly at the cell surface by DMT1, independently of transferring [29], [43]. 
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NEUROTOXICITY MECHANISMS  
 
OXIDATIVE STRESS THEORY 
 
Several studies have demonstrated that Mn is capable of inducing free radical formation 
and oxidative stress [46], [47] specifically mitochondrial oxidative stress. 
There are two major mechanisms by which Mn-induced oxidative stress can occur. One of 
the mechanisms is via the oxidation of dopamine and other catecholamines especially 
because Mn accumulates in dopamine-rich brain regions of rodents and primates (e.g., 
basal ganglia) [48]. Free radicals generated by Mn2+ ions have been proposed to increase 
the oxidation of catecholamines with more free radicals production and consequent 
oxidative stress [49], [50]. It has been demonstrated that Mn2+ catalyzes Fenton-like 
reactions that generate hydroxyl radical and trigger proteolytic degradation and protein 
turnover. Mn via spontaneous oxidation and dismutation, peroxidative activity, or oxygen 
radical-mediated oxidation, gives rise to Mn3+ which will oxidatively destroy dopamine and 
its precursor dihydroxyphenylalanine (DOPA) [50],[51].  
The other is via accumulation of Mn in the mithocondria, where interferes with proper 
respiration, thereby leading to excessive production of reactive oxygen species (ROS) 
[52], [53]. Mitochondria are critical for numerous essential aspects of cell function, from 
ATP energy production via the respiratory chain to steroid biosynthesis, heme assembly, 
pyrimidine biosynthesis, the tricarboxylic acid cycle, and apoptosis. Mitochondria are also 
the main producers of ROS within the cell [54]. 
Current evidence indicates that Mn binds to the inner mitochondrial membrane which is 
also the location of the electron transport system of the cell a site for production of oxygen 
free radicals. Small initial amounts of oxygen can be self-propagating via damage to the 
electron transport chain in mitochondria. When proteins or quinones that participate in 
transfer of electrons are damaged, the chain begins to donate electrons directly to 
molecular oxygen, thereby creating the highly reactive superoxide radical (O2·-). 
Oxidizing conditions within the cell may also lead to the oxidation of Mn2+ to Mn3+, as has 
been shown in vitro and this may be a possible key event in the development of 
cytotoxicity in brain following exposure to Mn [47]. Mn in any oxidation state will likely 
spontaneously give rise to infinitesimal amounts of Mn3+ [53], and HaMai et al. [55] 
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demonstrated that it can cause formation of ROS even at trace amounts. Mn3+ appears to 
be both a pro-oxidant as well as an inhibitor of mitochondrial respiration, leading to 
increased ROS formation [56]. 
Some of these mitochondrial events are significantly blocked by antioxidants, suggesting 
the involvement of oxidative stress in the mechanism of Mn-induced mitochondrial 
dysfunction [57]. Significant oxidative stress has severe effects on cell survival pathways, 
often leading to necrosis or apoptosis [58]. 
Interactions between Mn and Fe play a role in Mn toxicity. The co-accumulation of Fe and 
Mn in the globus pallidus raises the concern that iron may be a contributing factor 
facilitating neuronal cell loss during Mn intoxication [19]. 
 
 
REACTIVE OXYGEN SPECIES (ROS)  
 
ROS are produced as a normal product of cellular metabolism. However excessive 
amounts can cause deleterious effects.   
ROS are highly reactive and instable. They react with several cellular components 
including DNA, proteins, lipids/fat acids and carbonyl groups. These reactions can damage 
DNA, originate mitochondrial dysfunction and injury in cell membranes and eventually lead 
to cell death.  
Oxidative damage is caused by increased production of ROS and/or by reduced 
bioavailability of antioxidant defenses. This imbalance between pro-oxidants and 
antioxidants gives rise to cellular oxidative stress.  
 
Acceptance of a single electron by an oxygen (O2) molecule forms O2·-, which has one 
unpaired electron. O2·- is a major agent responsible for O2 toxicity and SODs (superoxide 
dismutase; namely Mn-SOD) are important antioxidant defenses. SODs remove O2 by 
converting it into hydrogen peroxide (H2O2): 
 
2 O2·- + 2 H+ → H2O2 + O2 
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H2O2 can act as an oxidizing agent, although it is poorly reactive. Unlike O2·-, however, 
H2O2 crosses cell membranes easily. H2O2 can be removed within human cells by the 
action of two types of enzyme, catalases and selenium-dependent glutathione 
peroxidases. 
H2O2 is known to be toxic to many systems, including nervous tissue. However, toxicity is 
not usually mediated by a direct effect of H2O2 except at high (and probably 
unphysiological) concentrations. Instead, H2O2 is a precursor of highly oxidizing, tissue-
damaging radicals. H2O2 reacts with divalent Fe (Fe2+) (and also with Mn2+) ions to form 
hydroxyl radical, ·OH, by the Fenton reaction, which may be represented by the overall 
reaction [42]: 
 
Fe2+ + H2O2 → Fe3+ + ·OH + OH-   
 
 
ANTIOXIDANTS  
 
ROS can be neutralized by molecules called antioxidants. Antioxidants such as ascorbic 
acid, glutathione and N-acetyl cysteine decrease ROS, protecting cells from cellular 
damage and/or death [59] by removing free radical intermediates, and inhibiting other 
oxidation reactions. As a result, antioxidants are often reducing agents such as thiols or 
polyphenols.  
Several studies have suggested that Mn toxicity is caused by its ability to increase ROS 
formation and decrease cellular protective mechanisms.  It has been shown that Mn 
decreases antioxidants such as, thiols, catalase, and glutathione (GSH) [59]. 
 
 
ENDOGENOUS ANTIOXIDANT: GLUTATHIONE 
 
 
  
 
 
Figure 1 - Chemical Structure of glutathione 
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GSH (L-γ-glutamyl- L- cysteinylglycine) is synthesized from L-glutamate, L-cysteine, and 
glycine in the presence of γ-glutamyl-cysteine synthase (GCS) and GSH synthase (GS) in 
consecutive steps. This synthesis occurs in virtually all types of cell types, being the liver 
the major producer and exporter of glutathione [56], [60, 61]. GSH has two important 
structural features: a sulphydryl group and a γ-glutamyl linkage [62]. The γ-glutamyl 
linkage promotes intracellular stability preventing GSH from being hydrolyzed by most 
peptidases and the sulfhydryl group is required for GSH’s functions [63], [61].  
GSH is important in maintaining the intracellular redox status of protein thiols, for 
protection against endogenous and exogenous sources of oxidative stress, and for the 
conjugation and excretion of toxic molecules (Meister, 1988, 1991). 
GSH exists in the reduced (GSH) and oxidized (GSSG) form. The two forms, oxidized and 
reduced, comprise the most abundant redox coupling mechanism of the cell. In healthy 
cells and tissue, more than 90% of the total glutathione pool is in the GSH form and less 
than 10% exists in the GSSG form. In the reduced state, the thiol group of cysteine is able 
to donate a reducing equivalent (H++e-) to other unstable molecules, such as ROS. After, 
glutathione itself becomes reactive, and readily reacts with another reactive glutathione to 
form GSSG.  
The endogenously produced H2O2 is reduced by GSH in the presence of selenium-
dependent GSH peroxidase [63], [64]. Studies have shown that GSH is critical in 
defending against both physiologically and pathologically generated oxidative stress. H2O2 
can also be reduced by catalase, which is present only in the peroxisome. In the 
mitochondria, GSH is particularly important because there is no catalase [63]. 
Severe oxidative stress may overcome the ability of the cell to reduce GSSG to GSH, 
leading to accumulation of GSSG within the cytosol. An increased GSSG/GSH ratio is 
considered indicative of oxidative stress [56].  
GSH cannot cross cellular membranes, but intracellular pools can be increased when N-
acetil-cysteine, which readily crosses membranes, is deacetylated into cysteine, a 
precursor for GSH [52], [56], [59].  
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EXOGENOUS ANTIOXIDANT: EBSELEN 
 
 
 
 
 
 
 
 
Ebselen [2-phenyl-1,2-benzisoselenazol-3(2H)-one] is a lipid soluble seleno-organic 
compound [60], [65] . 
The specificity for substrates ranges from H2O2 to smaller organic hydroperoxides and 
includes membrane-bound phospholipid and cholesterylester hydroperoxides. Since 
ebselen is effective against membrane hydroperoxides, it inhibits both nonenzymatic and 
enzymatic lipid peroxidation in vitro and has anti-inflammatory activity in various animal 
models [65]. Ebselen’s antioxidant and anti-inflammatory properties have been 
demonstrated in a variety of in vivo models [66].  
Contrary to the reductive detoxification of hydroperoxides, ebselen is a poor free radical 
scavenger and consequently this is not regarded as a significant component of its 
pharmacodynamic activity [67]. Ebselen is not a free radical scavenger per se, but mimics 
the enzyme glutathione peroxidase. Like these enzymes, ebselen acts with glutathione 
through a selenium core to eliminate hydroperoxides and lipoperoxides [60], [68, 69]. 
Therefore, ebselen, when combined with suitable thiol compounds such as glutathione or 
N-acetil- cysteine, it can reduce hydrogen peroxide to water and attenuate lipid 
peroxidation by reducing organic cholestrol, cholesterol ester- and phospholipid peroxides. 
Results of clinical trials indicate the benefit of ebselen as a neuroprotective agent because 
of the multiplicity of its mechanisms for inhibiting free radical-induced injury coupled with 
its lack of side-effects, good blood-brain penetrability and rapid absorption following oral 
administration [69], [70]. Unlike inorganic selenium and selenomethionine, ebselen is not 
toxic to mammals [60].  
Recently, a new property of ebselen to inhibit apoptosis has been demonstrated [71]. 
 
Figure 2 - Chemical Structure of Ebselen 
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ANTIOXIDANTS AS INDICATORS OF OXIDATIVE STRESS 
 
The presence of oxidants can be assessed by measuring species that are known to 
increase or decrease in response to oxidative stress. This includes ubiquitous 
antioxidants, such as GSH [52]. 
Experimental work suggests that Mn increases the production of free radicals measured 
as increased lipid peroxides, reduced glutathione, metallothionein [53], and other specific 
biomarkers derived from the effects of Mn on biogenic amines such as dopamine [72]. 
Severe oxidative stress depletes cellular GSH. In vitro studies showed that the inhibition of 
GSH synthesis and the consequent impairment of the neuronal antioxidant system activity 
plays a permissive role in oxidative stress-mediated Mn neurotoxicity [73]. 
 
 
BIOMARKERS OF EXPOSURE 
 
Biological markers can link the presence of a chemical in various environmental 
compartments to specific sites of action in target organs and to host responses [19]. 
Biomarkers can be xenobiotics themselves or a result of their metabolism.  
 
The strength of association between exposure biomarkers and the effect outcome was not 
often particularly strong, which may in part reflect uncertainty or limitations in how well the 
biomarker captures the external exposures contributing to toxicity [74].  
The identification and validation of exposure biomarkers is fundamental to human 
toxicology and risk assessment but it has been a challenge to identify and validate 
biomarkers for Mn exposure and effect [74]. And since Mn is an essential element, in 
normal conditions the concentrations in the body are controlled by homeostatic 
mechanisms regulating absorption, disposition, and excretion. These processes also play 
an important role in Mn toxicokinetics, contributing to the complexity that has been the 
validation of biomarkers of exposure for Mn. 
 
The assessment of Mn exposure, especially in human populations, is through Mn 
determination in blood and urine samples. Nevertheless, published literature reveals 
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substantial variability in blood Mn levels measured in exposed subjects. Lucchini et al. 
(1999) observed an association between blood Mn and exposure intensity [75]. One year 
later, Apostoli and co-workers investigated the suitability of blood and urine Mn levels on 
the exposure assessment and concluded that these two parameters can only discriminate 
between groups of occupationally exposed and control subjects [76].  
Ideally, biological markers of exposure should reflect an integration of the internalized 
dose over time. Recently Mn blood levels as exposure biomarker were described as 
limited and highly dependent on the exposure parameters [74]. Blood Mn alone appears to 
have utility only for group exposure surveillance, not showing a relation between the level 
of exposure and the blood levels. Besides, blood and urine Mn analysis don’t provide 
information about previous exposures, probably and partially due to Mn short blood half-
life (t1/2 < 2 h) and large volume of distribution, disappearing rapidly from the blood 
compartment [35].  
Mn in blood has been referred as an indirect reference to be associated to some other 
variables that could be affected by Mn exposure, the markers of effects [72].   
 
Since much of clinical diagnostic medicine relies on effects-related biomarkers [19] and the 
currently available tests (Mn in blood and urine) seem to fail in establishing this 
relationship, attention should be focused on other indicators [72], [76], [77]. 
 
 
BIOMARKERS OF EFFECT 
 
Biomarkers of effect, altogether with the already known and tested biomarkers of exposure 
could help establishing a correlation between the exposure and their consequences for the 
organism. Those with a better exposure-response relationship must be proposed and 
validated. 
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GSH 
 
As previously mentioned, oxidative stress is generally accepted as one of the mechanisms 
through which Mn toxicity acts. Alterations in brain GSH metabolism have been linked to 
oxidative stress and various neurodegenerative diseases [78]. 
As a result, oxidative stress can be indirectly assessed by measuring the levels of 
antioxidant species such as metallothionein and GSH. In postmortem studies of PD brains, 
the amounts of GSH in the substantia nigra were found reduced, which can be a good 
indication for the use of GSH in Mn neurotoxicity studies [53]. 
 
At the cellular level, it has been shown that Mn decreases antioxidants such as catalase, 
and GSH. This decrease in intracellular antioxidants is sustained by the observation by 
Sloot et al. that Mn induces ROS formation [59], [84].  
Much of the evidence supporting a role for oxidative stress in the toxicity of Mn comes 
from in vitro studies. Seth et al. observed that in Mn treated rat pheochromocytoma (PC12) 
cells there was a decrease in GSH content, catalase activity, and mitochondrial activity 
[56].  
But some in vivo studies have also come out with similar results. In 2000, Dorman et al. 
[79] detected significantly decreased striatal GSH levels following subchronic MnSO4 
inhalation and similar decreases in GSH concentrations in the cerebellum and 
hypothalamus following exposure to hureaulite. 
 
 
PROLACTIN  
 
It is known that Mn causes alterations in the cerebral dopamine [80], a fact that is tightly 
related to the psychiatric and expyramidal symptoms during Mn intoxication.  
Dopamine, within the pituitary, suppresses the secretory activity of specific pituitary cells 
called lactotrophs [81]. These cells are responsible for the secretion of an important 
hormone, prolactin. Dopamine acts by binding to D2-receptors on the lactotrophs and 
inhibits both the release and the synthesis of prolactin [82], [83]. 
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It is hypothesized that Mn exposure suppresses the inhibition of dopamine on and 
prolactin, and then an increase of prolactin may be observed [81], [84].  
Prolactin has been used as a biological exposure index of Mn exposure in several reports 
[72], [82, 84]  with inconclusive or negative results as well [85], [86]. 
 
 
ISOPROSTANES (F2-ISOP) 
 
Isoprostanes are prostaglandin – like compounds produced in vivo primarily by free 
radical-induced peroxidation of arachidonic acid [87], [88]. It has been established that 
measurement of F2-IsoP provides an important tool to explore the role of oxidative stress 
in human disease [87]. Measurement of F2-IsoP is at present regarded as a reliable 
approach for the assessment of oxidant stress status and free radical mediated lipid 
peroxidation in vivo [88]. Quantification of F2-IsoP is used as a reliable marker of lipid 
peroxidation in vivo.  
F2-IsoP are detectable in various tissues including the lung, liver, kidney and the brain, fat, 
muscle. They have also been found in measurable quantities in most of the biological 
fluids like plasma and urine, biological samples that can be easily obtained.  
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OBJECTIVES 
 
 
- To apply an in vivo assay to control the internal doses of exposure in rats exposed 
to repeated doses of Mn; 
- To correlate the biomarkers of exposure (blood and brain Mn levels ) with the 
biomarkers of effect (prolactin, GSH and behavioural assays) 
- To study the interference of ebselen in the toxicokinetics and/or toxicodynamics of 
Mn; 
- To clarify the interference of Fe in the absorption of Mn into the target organ 
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MATERIALS AND METHODS 
 
REAGENTS 
 
Manganese chloride tetrahydrate (MnCl2·4H2O; 99,99%, Sigma-Aldrich)  
 
 
 
 
 
 
 
 
  
 
 
Ebselen (>99% Appli Chem, Biochemica)  
 
Nitric Acid (HNO3; 65% Suprapure; Merck) 
 
Hydrogen Peroxide (H2O2, 30%; Aldrich) 
 
 
ANIMALS  
 
Male Wistar rats (150-171g) were provided by Charles River Laboratories ®, Barcelona. 
The animals were housed in an independent room, with 12-h light/dark cycle, humidity of 
50–70% and a temperature of 24°C with free access t o water and food. Food was supplied 
as pellets adequated for normal growth, reproduction, and maintenance.  
The general condition of all animals was checked every day. All animals received human 
care according to the criteria outlined in the “Guide for the Care and Use of Laboratory 
Figure 3 - Manganese chloride. 
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Animals” prepared by the National Academy of Sciences and published by the National 
Institutes of Health. 
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0 
Animal Acclimation 
TRE ATMENT  
Animal’s Sacrifice  
4 Doses Group 
Animal’s Sacrifice  
8 Doses Group 
 
IN VIVO ASSAYS 
 
A sub-acute experiment was performed using male wistar rats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According with normal procedure, an acclimatization period of 10 days was assured for all 
animals. During this period, 24 h urine was collected and behavioral analysis was 
performed. 
Rats were randomly assigned into 2 main groups and then distributed into 6 groups of 5 
animals, as illustrated below.  
 
 
 
 
 
 
 
 
 
 
 
4 Doses Group 8 Doses Group 
Control 
Mn 4 doses 
Control 
Mn 8 doses Mn+Ebselen 
Ebselen 
Figure 4 - Experimental Design. 
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Solutions of MnCl2 (10 mg/Kg), MnCl2 (10 mg/Kg), plus ebselen (15 mg/Kg), and ebselen 
(15 mg/Kg) were prepared and administered by i.p. injection to the rats once daily, for 4 
and 8 consecutive days, according with the experimental design. Control animals received 
daily injections of the equivalent volume of sterile saline. 
 
 
 
 
 
 
 
 
 
During the experiment body weight was measured, the behavior was observed and 24h 
urine was collected, using metabolic cages (Fig. 6). 
After anesthetized and before the sacrifice of the rats, blood was collected by cardiac 
puncture. After collected, blood was divided by two sterile tubes, one for whole blood 
analyses (heparinized tube) and other for serum. 
After the sacrifice of the animals, brain, liver and kidneys were dissected out, rinsed with 
cold 0.9% sterile saline, dried out in filter paper, weighted and stored in individual 
polypropylene tubes. All samples were immediately frozen at -80ºC.  
 
 
 
 
 
 
 
 
 
 
Figure 5 – I.p  injection technique.  
Figure 6 - Metabolic Cage. 
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After the in vivo assay, several parameters were determined using analytical procedures. 
Mn was measured in brain and blood by atomic absorption spectrometry; Fe in brain was 
also measured by atomic absorption; GSH was analyzed by high performance liquid 
chromatography (HPLC) and prolactin levels were determined by an enzyme 
immunoassay method.  
 
 
 
ANALYTICAL METHODS 
 
 
DETERMINATION OF MN AND FE IN BIOLOGICAL SAMPLES 
 
Microwave-Assisted Acid Digestion - Brain and blood samples were digested prior to 
GFAAS analysis, with an oxidizing acid mixture of 4:1 (v/v) 65% suprapure nitric 
acid:hydrogen peroxide (30%). Samples were weighted (80 mg of the brain homogenate) 
directly on the Teflon cups and 2.9 ml of the oxidizing mixture was added to each cup. The 
cups were sealed, placed inside the respective bombs (Parr Microwave Acid Digestion 
Bombs ®) and subjected to microwave irradiation for 30’’ (900 W).  
The resulting solutions were transferred to 5 ml volumetric flasks and 100 µl of the 
chemical modifier magnesium nitrate (Mg(NO3)2·6 H2O) were added to each balloon. 
Volumes were completed with deionized water. Solutions were kept at 4ºC until analysis. 
 
Graphite Furnace Atomic Absorption Spectrometry (GFAAS) - Iron and Mn 
concentrations were determined by graphite furnace atomic absorption spectrometry 
(GFAAS), using a PerkinElmer AAnalyst™ 700 atomic absorption spectrometer equipped 
with an HGA Graphite Furnace , a programmable sample dispenser (AS 800 Auto 
Sampler), and WinLab 32 for AA software at Laboratório de Métodos Instrumentais de 
Análise (Faculdade de Farmácia da Universidade de Lisboa). Mg(NO3)2·6 H2O (0.84 
mol/L) was used as a chemical modifier.  
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Samples were measured once and every measurement consisted of two injections into 
graphite furnace. Results were expressed as micrograms of Mn per g of brain tissue and 
micrograms of Mn per milliliter of blood. Calibration curves were obtained with standard 
solutions of 10, 15 and 25 µg/L of MnCl2. The limit of quantification determined was 0.05 
µg/L.  
 
 
 
ANALYSES OF GSH IN BRAIN 
 
Sample Preparation - Brain tissue was homogenized, and samples were weighted 
(approximately 20 mg). PBS solution was added, 10 times the weight in volume (example: 
for 20 mg sample add 200 µL of PBS) and samples were macerated. Samples were then 
sonicated (30 cycles; Conditions: Cycle 0.5, Amplitude 100) and centrifuged for 10’ at 10 
000 rpm. The supernatant were collected to 1 ml eppendorfs and samples were analyzed 
by HPLC. 
To prevent oxidation of thiols during sample manipulation (which represents the major 
problem in such determinations) samples were handled on ice whenever possible and only 
non-metallic utensils were used.  
 
HPLC analyses - GSH levels in brain tissue were measured by HPLC at the Centro de 
Patogénese Molecular, Lisboa. HPLC was equipped with a Supelcosil LC-18-S reverse 
phase column, a Waters 2475 fluorimeter detector and a Waters 2695 separation module. 
HPLC system was compatible with Water Empower II Software.  
 
 
DETERMINATION OF PROLACTIN IN SERUM 
 
Serum prolactin was quantified by an enzyme immunoassay (Citomed ®). Plates were 
read in an Anthos Zenyth 3100 microplate detector. Limit of quantification was 0.6 ng/ml.  
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BEHAVIORAL ASSAYS 
 
 
 
  
 
 
 
 
 
 
 
 
Behavior is a potencially sensitive endpoint of chemical-induced neurotoxicity. 
Neurobehavioral tests are recommended in the risk assessment process. Motor activity 
measurements are accepted as sensitive, reliable, and efficient [89].    
Motor activity was assessed on Control and Mn (8 doses) treated groups for two 
occasions: just before the beginning of the experiment and on the last day of treatment. 
The order of testing was randomized, and the observer was maintained blind to the 
treatment of each animal. 
Two behavioral parameters were studied: ambulation (number of crossings within 5 min in 
an open field) and rearing (number of times within 5 min where both forelegs were risen 
from the floor in the same open field). The floor of the open field measured 60 cm × 90 cm 
and was divided into six equal squares (Fig. 7 and 8). The floor was surrounded by a 30-
cm-high opaque wall. The rats were tested individually, and after each session, the open 
field was cleaned. Because a large number of environmental conditions can affect motor 
activity (e.g., sound level, cage design, lighting, temperature, and humidity, or odors), 
records took place in an independent room, at a fixed hour of the day with controlled light 
and sound. At the beginning of each session the animals were placed at the centre of the 
open field, and the behavior of each rat was observed for 5 min [90], [91]. 
 
 
Figure 8 – Experimental apparatus for behavioral 
assay 
Figure 7 - Top view of the experimental 
apparatus 
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STATISTICAL ANALYSIS  
 
All analyses were conducted using MICROSOFT OFFICE EXCEL® 2003 and SPSS 
STATISTICS® version 16.0, 2007. All results were analyzed for normal distribution with 
Kolmogorov-Smirnov test. Variables were compared by tests for homogeneity of variance 
(Levene’s test) and one-way analysis of variance (ANOVA). For multiple comparisons, 
ANOVA complemented with post hoc Tukey HSD (all pairwise) and Dunnett’s test 
(pairwise versus control) was performed. Data was presented as mean values ± standard 
error of the mean (S.E.M.). Limit for statistical significance was set at p<0.05 (significance 
level of 95%).  
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RESULTS  
 
 
BEHAVIORAL ASSAYS 
 
Behavioral parameters were studied for control and 8 doses groups for two parameters 
and two times: before the beginning of the experiment and at the end, before the sacrifice 
of the animals. After observing our results, we can say that MnCl2 treated rats had 
decreased spontaneous activity (p<0,05), for both ambulation and rearing (Figures 9 and 
10).  
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Figure 9 – Ambulation in rats exposed to 8 doses of MnCl2 and control 
group. Each bar represents the mean ± S.E.M. (* p < 0.05). 
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BODY WEIGHT AND RELATIVE ORGAN WEIGHT 
 
Along the experiment body weight was registered and it was observed that in treated 
animals the body weight gain was significantly lower than in control. Treated animals 
gained significantly less weight than the control groups (Figure 11). If we compare Mn plus 
ebselen group with either control or 8 doses group, a significant decrease in body weight 
gain is also observed (Figure 12). 
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Figure 10 - Rearing in rats exposed to 8 doses exposure to MnCl2 and 
control group. Each bar represents the mean ± S.E.M. (* p < 0.05). 
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Figure 11 - Growth rate of rats. Values are means ± S.E.M. (p<0.0001, 
compared to control; ∆ p<0.0001, compared to Mn 4 doses group. 
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Relative organ weight (ROW), the ratio of organ to body weight, was measured for liver 
and brain. Figures 13-16 show the changes in liver and brain ROW. Brain ROW was 
increased in all exposed groups but only 8 doses treated rats and Mn plus Ebselen treated 
rats showed significant differences compared to control (p<0,05).  
Liver ROW was significantly increased (p<0,001) in 8 doses Mn-treated group compared 
to control (Figure 15 and 16). 
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Figure 12 - Growth rate of the rats. Values are means ± S.E.M. (* p < 
0.0001, compared to control; Δ p<0.0001, compared to Mn 8 doses). 
Figure 13 - Relative brain weight. Values are means ± S.E.M. (* p < 0.05, 
compared to control). 
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Figure 14 - Relative brain weight. Values are means ± S.E.M. (* p < 0.05, 
compared to control; Δ p<0.05, compared to ebselen). 
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Figure 15 - Relative liver weight. Values are means ± S.E.M. (* p < 0.0001, 
compared to control). 
Study of biomarkers to evaluate the protective effects of antioxidants against manganese neurotoxicity 
CHAPTER V – RESULTS 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mn CONCENTRATIONS IN BLOOD 
 
At the end of the experiment, Mn was measured in blood. Comparing the two Mn doses, 
both groups had higher Mn levels in blood but the 4 doses group showed no statistical 
differences when compared to control (Fig. 17).  In the 8 doses group and Mn plus ebselen 
group significantly higher values of Mn in blood were observed compared to control 
(p<0,0001) (Fig. 18).  
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Figure 16 - Relative liver weight. Values are means ± S.E.M. (* p < 0.0001, 
compared to control). 
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Figure 17 - Levels of Mn in blood. Bars represent the mean ± S.E.M. (*p< 
0.0001, compared to control; Δ p<0,0001, compared to 4 doses group). 
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Mn CONCENTRATIONS IN THE BRAIN 
 
 
Mn was also measured in brain. If we compare both Mn treated groups (4 and 8 doses) a 
significant difference between them is observed (Fig. 19). 
Brain Mn content increased significantly for all Mn-treated groups. Mn plus ebselen and 8 
doses groups had significantly higher levels of Mn in the brain when compared to control (* 
p<0.0001). The 8 doses group had also higher and significantly different levels than the 
Mn plus ebselen group (∆ p<0.0001) (Fig. 20).  
 
 
 
0,00
0,10
0,20
0,30
0,40
0,50
0,60
Control Mn 8 doses Ebselen Mn+Ebselen
µ
g
 M
n
/m
l 
b
lo
o
d
* 
* 
∆ 
Figure 18 - Levels of Mn in blood. Bars represent the mean ± S.E.M. (* p < 
0.0001, compared to control; Δ p<0.0001, compared to Mn 8 doses). 
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Figure 19 - Levels of Mn in brain tissue. Bars represent the mean ± S.E.M. 
(* p < 0.0001, compared to control; Δ p< 0.0001, compared to 4 doses 
group). 
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Figure 20 - Levels of Mn in brain tissue. Bars represent the mean ± S.E.M. 
(* p < 0.0001, compared to control; Δ p<0.0001, compared to ebselen 
group; Ο p<0.0001, compared to 8 doses group). 
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GSH LEVELS IN THE BRAIN 
 
A decrease of GSH levels in brain was observed in groups exposed to Mn, although the 
decrease was only significantly different in the 8 doses group compared to control 
(p<0.0001) (Fig. 21). Concerning Mn plus ebselen group, no differences were observed 
between this group and the 8 doses group (Fig. 22).  
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Figure 21 - Levels of GSH in brain tissue. Bars represent the mean ± S.E.M. 
(* p < 0.0001, compared to control). 
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Figure 22 - Levels of GSH in brain tissue. Bars represent the mean ± S.E.M. (* p < 
0.0001, compared to control; Δ p< 0.0001, compared to ebselen). 
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PROLACTIN IN SERUM 
 
Prolactin levels were measured in serum and the values observed were significantly 
increased in the 4 doses groups (p<0.001) and 8 doses group (p<0.0001), compared to 
control (Fig. 23). If we compare the Mn plus ebselen group with the 8 doses group, there is 
a significant decrease of prolactin values compared with the exposed group. We didn’t find 
any differences between the co-exposed group and the control (Fig. 24). 
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Figure 23- Prolactin levels in serum. Bars represent the mean ± S.E.M. (* p< 
0.0001; Δ p< 0.0001, compared to 4 doses group). 
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Figure 24 - Prolactin levels in serum. Bars represent the mean ± S.E.M. (* p< 
0.0001compared to control). 
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Figure 25 - Correlation between Mn levels in blood and Mn levels in 
brain.        Mn levels in blood;       Mn levels in brain 
Figure 26 - Correlation between prolactin levels in serum and Mn levels 
in brain.       Prolactin in serum;      Mn levels in brain 
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The levels of Fe were determined in blood samples. Fig. 27 and 28 show a slight decrease 
of Fe contents in the exposed groups; however no significant difference from control was 
observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 - Levels of Fe in brain tissue. Bars represent the mean ± S.E.M. 
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Figure 28 – Levels of Fe in brain tissue. Bars represent the mean ± S.E.M. 
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DISCUSSION 
 
Although Mn is an essential metal, repeated exposure may originate neurotoxic effects as 
a consequence of its accumulation in the brain. The study of the neurotoxic effects of Mn 
holds special clinical relevance in occupational, clinical and environmental toxicology [92] 
since overexposure can lead to progressive, permanent, neurodegenerative damage, 
resulting in a syndrome similar to idiopathic Parkinson’s disease [10]. 
Consequently it is fundamental the development of biomarkers to control and prevent the 
overexposure and specially the appearance of neurotoxic effects.   
 
The development of our experimental work consisted of an in vivo assay with Wistar rats 
exposed to repeated doses of MnCl2.  
During the assay we followed up the animals’ welfare through the ongoing assessment of 
animal behaviour. The observation of animals’ behaviour can be used as an indicator of 
potential neurotoxic effects. In our study motor activity measured at the end of the 
experiment (after 8 doses administration) revealed a decreased in spontaneous activity for 
both ambulation and rearing of Mn-treated animals when compared to control (see Fig. 9 
and 10). Decreased spontaneous activity in open field activity has been previously 
observed in rats exposed to MnCl2 [93], [94]. The observed decrease in motor activity in 
rats exposed to Mn can be explained as a result of the effects of Mn in the dopaminergic 
system [93], [95], [96]. The body weight of the animals was also assessed along the 
experiment, and it was observed a decrease in body weight gain in treated animals (Fig. 
11 and 12). These results are consistent with other studies results [94], [96], [97]. 
Currently, there are no valuable or consistent biomarkers that correlate the Mn exposure 
with its neurotoxic effects. Among those that are used to monitor Mn exposure we selected 
in our experiment the brain and blood Mn levels. However, Mn has a short blood half-life 
(t1/2 < 2 h) [35] and is quickly eliminated from the blood circulation, following exposure.  
Looking at our results in Fig. 17 the levels of Mn in blood are higher in both groups 
exposed to Mn when compared to control. However, those differences are only statistically 
significant for the 8 doses group. Results from the 4 doses treated group compared with 
control show higher but not significantly different blood Mn levels. These results agree with 
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others that suggested that blood manganese concentration is a poor biomarker for short-
term manganese exposure [79]. 
Previous research demonstrated that Mn exposure originates quick absorption [44] and 
Mn accumulation in the brain [99], [100], [101]. In addition, it is referred that the route of 
administration, the dosage [34, 98] and the fact that the Mn turnover in brain is much 
slower than in other parts of the body [98], [93] are the main factors which determine the 
accumulation of Mn in the brain. Mn concentrations in blood must exceed the liver 
clearance capacity to allow Mn uptake by the brain [44].  
As expected, our analysis of brain samples of exposed rats confirmed Mn accumulation in 
the brain. Rats exposed to repeated doses (4 and 8 doses) had higher and significantly 
different brain Mn concentrations when compared to control. After 8 doses, Mn 
concentration in brain was around 5 times higher than control values and almost 3 times 
higher after 4 doses administration allowing us to conclude that the increase of Mn in the 
brain for these two doses was dose-dependent [94] (Fig.19). Our results are consistent 
with the results obtained by other authors [34], [44], [93], [97]. 
 
In this study we also investigated biomarkers of effect as endpoints of toxicity. The 
selection of the endpoints was made based on the proposed mechanisms of neurotoxicity. 
One of those proposed mechanisms of Mn toxicity is through oxidative stress.   
In vivo [53], [102] and in vitro studies show that Mn can instigate the production of ROS 
with depletion of antioxidant defense mechanisms [99]. The effective control of oxidative 
stress depends largely on the levels of antioxidants present in the cell. So, oxidative stress 
can be indirectly measured through the study of antioxidants, such as GSH. Alterations in 
brain GSH have been linked with oxidative stress and various neurodegenerative diseases 
[78], [103]. Recently, an in vitro study developed in our Lab showed a decrease of GSH 
levels in rat brain endothelial cells exposed to several concentrations of MnCl2 [104].  
Our results show (Fig. 21) a significant decrease in GSH levels in rats exposed to 8 doses 
of MnCl2 while the 4 doses group of rats show a decrease but with no statistical 
significance. A decrease has already been observed in vivo in rats exposed to Mn  [100] 
and confirm the occurrence of oxidative stress in the cells of the rat brain. 
Nevertheless, alterations in antioxidant defenses are not the only known consequences of 
Mn induced toxicity. Dopamine and other catecholamines oxidation, and concurrently 
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amplification of the formation of ROS, is another potential mechanism described for Mn 
toxicity [105]. Ample experimental evidence shows that dopamine inhibits prolactin release 
from pituitary lactotrophs both in vivo and in vitro [106]. Prolactin is a polypeptide hormone 
that has been studied has a potential biomarker for Mn exposure and indicator of 
neurotoxicity. Based on this, it was expected an increase of prolactin levels after Mn 
exposure, since dopamine inhibition of prolactin release would be reduced. This 
assumption was confirmed by our analysis (Fig. 23). In our experiment we found increased 
levels of serum prolactin in rats exposed to Mn, for both 4 and 8 doses. Those values are 
significantly different from the control groups and different between each other. As pointed 
out for Mn levels in brain, also for prolactin a dose-response correlation was observed as 
described in Fig. 26. The correlation between Mn values in blood and brain was also 
performed (Fig. 25) to the 4 doses and 8 doses group but prolactin has shown to be a 
better and more sensitive biomarker, since correlates more suitably the Mn concentration 
with the effects, for both doses administered.  
In our work we also investigate the oxidative stress induced by Mn using an antioxidant, 
ebselen. We wanted to compare the 8 doses of Mn with rats co-exposed to Mn and 
ebselen (also 8 doses), trying to see if ebselen could act as a protector against Mn toxicity 
(Fig. 18 and 20).  
Ebselen seems to interfere with Mn toxicokinetics. Mn plus ebselen treated animals had 
significantly lower values of Mn in brain, when compared to 8 doses group. Concerning the 
levels of GSH, no differences were found between Mn plus Ebselen group and their 
control. Ebselen has been exhaustively studied for the last decade, with proved capacity to 
avoid GSH depletion in vivo [107], [108]; however the direct effect of ebselen via 
glutathione reduction doesn’t seem to be sensed by cells until large concentrations (mM) 
of glutathione become oxidized [70]. An explanation for the lack of such results in our 
study may rely on the dosage administered. Ebselen dosage may have been insufficient to 
protect cells from glutathione oxidation.   
Finally, the interference of Fe in the mechanism of transport of Mn to the brain was 
investigated through the analysis of Fe levels and by comparing those results with Mn 
brain content. 
According with some studies [109], [110] Fe homeostasis may play an important role in the 
regulation of Mn transport across the BBB. Evidence indicates that Mn toxicity appears to 
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be associated with altered Fe metabolism at both systemic and cellular levels [111-113]. 
Previous work indicates that Fe deficiency results in increased brain Mn levels [72], [114], 
[115]. High Fe food intake reduces the concentration of Mn in the CNS and Fe overload 
significantly decreases the uptake of Mn to the brain [6]. Since Mn and Fe compete for the 
same transporters, it is not surprising that an increase in brain Mn is linked to a decrease 
in Fe [116]. We found very small differences between the exposed groups and control, but 
those differences were not significant. Since the number of days of exposure was reduced 
(maximum 8 doses) and knowing that the brain permeability to manganese is higher than 
that to Fe [117], [118], Mn exposure could have failed to significantly affect Fe balance in 
such a short exposure time.  
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CONCLUSIONS 
 
By gathering and interpreting all the results, some conclusions arise: 
 
- Mn accumulates in the brain in a dose-dependent manner; 
 
- Mn levels in blood increase with Mn exposure. However, this increase doesn’t 
reflect its accumulation in the brain  
 
- Prolactin levels in serum show a good correlation with Mn levels in brain, for both 
exposure doses (40 and 80 mg/Kg of MnCl2); 
 
- For the higher exposure dose, a positive relationship between the biomarkers of 
exposure (blood and brain Mn levels) and effect (prolactin, GSH and behavioural 
assays) was found. 
 
- The antioxidant ebselen didn´t interfere significantly in the increase of neurotoxic 
endpoints observed in the higher Mn exposed group; however a significant 
reduction in the accumulation of Mn in the brain of the co-exposed group was 
observed. 
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